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Introduction
I have studied and worked with non-Hodgkin lymphoma (NHL) for at least 16 years in 
the Hospital das Clínicas and Instituto do Câncer do Estado de São Paulo of the Faculdade de 
Medicina da Universidade de São Paulo (FMUSP).
Last year we attended 300 new patients with NHL and 49.5% (almost 150 patients) 
had diffuse large B-cell lymphoma (DLBCL)(1). This is in agreement with the literature that 
describes DLBCL as the most common subtype of NHL (30% to 35%). 
Over the last four decades there has been a significant increase in the 5-year survival of 
patients with DLBCL. This is due to the development of anthracycline-based polychemotherapy 
regimens such as is used in the CHOP protocol and more recently, with the incorporation of 
immunotherapy with the monoclonal antibody anti-CD20 (rituximab) in the CHOP-regimen. 
However, 10% to 15% of DLBCL patients remain unable to acquire complete remission (CR) 
even in the rituximab era and 30% to 50% of the patients that acquire a first CR will relapse(2). 
As we have almost 150 patients per year with DLBCL in our service, we can assume that about 
60 patients per year will have refractory or relapsed disease. Hence, we have a huge challenge 
every year with the main question being what is the best approach to offer to relapsed DLBCL 
patients? The unquestionable answer to this question is that patients have to be salvaged with 
a second line regimen and it is always possible to consolidate the patient with autologous stem 
cell transplantation (ASCT). In this article I will try to examine the level of evidence of this 
approach and to introduce the experience I acquired over these 16 years of NHL.
 
Diagnosis and restaging relapsed diffuse large B-cell lymphoma patients 
If patients present clinical features or findings by imaging that are suggestive of relapsed 
disease, they should be submitted to biopsy for confirmation. Confounding conditions such as 
infection and carcinoma should be discarded. Additionally, the histology must be reanalyzed 
in relapsed disease because it can change and this information is essential for the best 
management of the patient. If relapsed lymphoma is confirmed, patients should be restaged. 
They have to be submitted to the same exams recommended at diagnosis such as CT, PET/CT, 
bone marrow biopsy and others such as brain nuclear magnetic resonance and cerebrospinal 
fluid analysis depending on the symptoms. 
Patients relapsed within the first five years after CR are defined as early relapse and after 
five years as late relapse. Patients with refractory disease present worse prognosis in salvage 
therapy than patients with relapsed disease. The prognostic factors of the relapse must also be 
investigated and the molecular subtype of DLCBL must be identified.
Treatment for relapsed diffuse large B-cell lymphoma
In our institution we use consolidation using ASCT as the first choice for patients with 
relapsed DLBCL. 
The first randomized prospective study carried out to specifically test the role of the ASCT 
in DLBCL was the PARMA study. In this trial, patients with relapsed and chemotherapy-
sensitive DLBCL were randomized to salvage chemotherapy with a cisplatinum and 
cytarabine-based regimen alone or in combination with ASCT. The disease free survival 
(DFS) and overall survival (OS) were significantly higher in the transplantation arm 
compared with the chemotherapy alone arm (46% and 53% vs. 12% and 32%, respectively). 
However, patients resistant to chemotherapy presented significantly worse prognoses than 
chemotherapy-sensitive patients [1-year progression free survival (PFS) of 22% vs. 5-year 
PFS 43%]. However, this study only enrolled under 60-year-old patients(3).
A second analysis of the PARMA study was performed to evaluate the international 
prognostic index (IPI)(4) for DLBCL at relapse. The overall responses (ORs) of patients after 
2 cycles of dexamethasone, cytarabine and cisplatinum (DHAP) were 77%, 54%, 55% and 
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42% in patients with IPIs of 0, 1, 2 and 3, respectively (p-value = 
0.02). Thereafter, the CR rates were 33%, 29%, 20% and 0% for 
the same groups (p-value = 0.03). The OS rates at 5 years were 
46%, 25%, 25% and 11%, respectively (p-value = 0.001). After 
the first 2 cycles of DHAP there was a second randomization 
where patients were selected to receive 2 more cycles of DHAP 
or ASCT. The IPI at relapse was highly correlated to the OS in 
patients treated in the DHAP arm (5-year OS of 48%, 21%, 33% 
and 0% for IPI 0, 1, 2 and 3, respectively; p-value = 0.006) but 
not in the ASCT arm (5-year OS of 51%, 47%, 50% and 50% 
for IPI 0, 1, 2 and 3, respectively; p-value 0.90). Patients with 
an IPI higher than 0 presented greater benefit to ASCT, but there 
was no significant benefit in patients with IPI = 0 compared to 
consolidation with DHAP alone (p-value = 0.50). It is important 
that ASCT is available in face of age and co-morbidities(5).
Recently, another multicenter phase 2 trial, the Collaborative 
Trial in Relapsed Aggressive Lymphoma (CORAL) compared 
the rituximab, ifosfamide, carboplatin and etoposide (R-ICE) 
with rituximab, dexamethasone, cytarabine and cisplatinum 
(R-DHAP) protocols for salvage therapy of patients with 
relapsed DLBCL. The second end point was to evaluate the role 
of rituximab maintenance after ASCT. Different to the PARMA 
study, the CORAL trial also enrolled patients with relapsed and 
refractory DLBCL after the CHOP or R-CHOP regimens. Patients 
were first randomized for salvage with R-ICE and R-DHAP. Also 
the impact of previous use of rituximab, of relapsed vs. refractory 
disease, and relapse before or after 12 months of induction 
therapy should be taken into account(6). 
After 3 cycles of R-ICE or R-DHAP, chemosensitive 
patients were consolidated with ASCT after etoposide, cytarabine 
and melphalan (BEAM) conditioning. Thereafter patients were 
selected by a second randomization for maintenance with 
rituximab or observation. The authors found no differences 
between R-DHAP or R-ICE as salvage for DLBCL patients (OR = 
63%) and 50% for ASCT. Moreover, the OS and DFS after ASCT 
were similar for both groups treated with R-DHAP or R-ICE. 
Patients treated with rituximab as first line showed lower response 
to salvage therapy than patients not treated with rituximab before 
(51% vs. 83%; p-value = 0.001). The 3-year event free survival 
(EFS) was 21% for patients exposed to rituximab and 47% for 
rituximab-naïve patients. Patients that presented relapse less than 
1 year after induction therapy also had poor outcomes similar 
to those observed for patients refractory to the salvage regimen. 
In this last group of patients the outcome was very poor with a 
minimal probability of cure(6). 
The European Blood and Bone Transplantation Registry 
published a retrospective study with 470 patients to evaluate 
the impact of ASCT in patients in a second CR after salvage 
therapy. In this study 351 (74%) patients were rituximab-naïve 
before ASCT and 119 (25%) received rituximab before ASCT. 
The median duration of the first CR was 11 months and the 
median time from diagnosis to ASCT was 24 months. The most 
common conditioning regimen was BEAM (67%). After ASCT, 
the 5-year OS was 63% (95% confidence interval: 58%-67%) 
and 5-year DFS was 48% (95% confidence interval: 43%-53%). 
The main predictive factor for DFS was the duration of the 
first CR (median: 51 months vs. 11 months; p-value < 0.001). 
Patients relapsed within 1 year of the first CR had the worst 
prognosis (median: 6 months vs. 47 months; p-value < 0.001)
(7)
. According to the literature ASCT provides a significant 
benefit for survival and it is recommended as part of salvage 
therapy for patients with chemosensitive relapsed DLBCL 
with an evidence level 1+ characterized by existence of well-
conducted meta analyses or systematic reviews of randomized 
controlled trials(3,6,8,9). However, there is no randomized trial 
evaluating the best conditioning regimen for ASCT; the most 
common used are 1-3-bis-chloroethyl-nitrosurea (BCNU), 
BEAM and cyclophosphamide, carmustine, etoposide (CBV). 
Radiotherapy may be used in bulky lesions as consolidation after 
ASCT and maintenance with rituximab after ASCT increases 
PFS but not the OS. However, as prolonged cytopenias and 
increased infections have been reported with this strategy it is 
not recommended outside of clinical trials. On the other hand 
the role of ASCT for refractory DLBCL is limited and these 
patients must be enrolled in clinical trials. The recommended 
standard source of hematopoietic stem cells for ASCT is the 
peripheral blood (PBSCT) instead of bone marrow because it is 
related with lower rate of death due to infection(9). A randomized 
study comparing autologous PBSCT versus BMT for aggressive 
lymphomas (61% DLBCL) showed that patients who underwent 
autologous PBSCT had a significantly longer OS, but not EFS 
in relation to autologous BMT patients(10).
Therapy of relapsed diffuse large B-cell lymphoma 
in patients ineligible for autologous stem cell 
transplantation
According to the literature, the outcomes of relapsed 
DLBCL are worse for over 60-year-old patients than for younger 
patients. The PARMA study did not enroll over 60-year-old 
patients and there are no comparative data for ASCT versus 
non-transplantation as salvage therapy in this patient group. 
A retrospectively study evaluated 2612 patients with DLBCL 
submitted to ASCT; 463 (18%) patients were older than 60 years 
(median: 63 years). When compared to the 2149 patients younger 
than 60 years old, the elderly patients more frequently received 
at least two treatment lines (76% vs. 57%; p-value < 0.001), were 
less commonly in first CR at the time of transplantation (23% 
vs. 30%; p-value = 0.005) and there was a longer time between 
diagnosis and transplant (median time 14 months vs.7.5 months; 
p-value < 0.001). Non-relapse mortality was higher in elderly 
patients at 100 days (4.4% vs. 2.8%), at 1 year (8.7% vs. 4.7%) 
and at 3 years (10.8% vs. 6.5%; p-value = 0.002). With a median 
follow-up of 12 months for surviving patients in the elderly group 
and 15 months for the younger group, the risk of relapse was 38% 
and 32%, respectively (p-value = 0.006). The PFS was 51% and 
62%, respectively at 3 years (p-value < 0.001) and the OS was 
60% vs. 70%, respectively at 3 years (p-value < 0.001). Outcomes 
from some studies provide evidence on the use of ASCT as 
salvage for over 60-year-old patients. We can conclude that age 
greater than 60 years in itself is not a contraindication for ASCT. 
There is no upper age defined to limit ASCT, but outcomes, such 
as transplant-related mortality, relapse and survival, in older 
adults are not as good as in younger patients(11,12).
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The PARMA and CORAL trials showed that relapsed 
DLBCL patients not submitted to ASCT present a low chance 
of survival at five years. Usually these patients are older and the 
toxicity is high, causing a high level of morbidity and mortality. 
These patients have to be treated palliatively trying to maintain 
the best quality of life usually with oral agents or radiotherapy for 
localized disease.
Survival predictive factors in relapsed diffuse large 
B-cell lymphoma
Two main predictive indexes have been developed to 
discriminate how patients are more able to acquire CR and 
their chance of relapse. The first one was the IPI. Based on five 
factors (age, Ann Arbor stage, serum lactate dehydrogenase level, 
performance status and number of extranodal sites) this index 
is today used throughout the world. In the IPI, there are four 
groups of risk that can predict different 5-year survival rates. In 
patients with low risk IPI (0-1) the 5-year survival rate is 73%, 
in intermediate-low risk (IPI 1-2) it is 51% and for intermediate-
high (IPI = 3) and high risk (IPI ≥ 4) the 5-year survival rates 
are 43% and 26%, respectively(4). The IPI remains an important 
survival predictive index for relapsed DLBCL(5). 
Another important and robust predictive factor for survival 
in DLBCL is based on the gene signature of the tumor cells that 
identify two molecular subgroups of DLBCL. The germinal center 
DLBCL (GC-DLBCL) subtype show tumor cells with a gene 
signature similar to that found in B-cells from the normal germinal 
center and the activated B-cell (ABC) or post-germinal center 
DLBCL (Non-GC) a subtype that has a gene profile usually found 
in normal activated B-cells. Patients with the GC-DLBCL subtype 
present significantly higher survival rates compared to patients with 
the non-GC-DLBCL subtype treated with CHOP or R-CHOP(2). 
As showed by the CORAL trial, the cell of origin of DLBCL 
remains a prognostic factor for relapsed/refractory patients. 
Germinal center B (GCB)-like DLBCL was significantly 
associated with a better PFS in the R-DHAP arm. However, the 
presence of the c-MYC gene rearrangement was significantly 
correlated with worse PFS (p-value = 0.02) and worse OS 
(p-value = 0.04). Prior exposure to rituximab (p-value = 0.0052), 
a high risk of age-adjusted IPI (p-value = 0.039), and FoxP1 
expression (p-value = 0.047) were also related to worse prognoses 
in relapsed/refractory DLBCL(13). 
The results of a (18)F-fluoro-deoxyglucose positron 
emission tomography (FDG-PET) scan after at least two cycles 
of salvage chemotherapy and before ASCT are correlated with 
predictive factor for relapsed/refractory DLBCL. A study showed 
that FDG-PET-negative patients before ASCT had better PFS 
and OS after ASCT. A positive FDG-PET scan after salvage 
chemotherapy and prior to ASCT indicated an extremely poor 
chance of durable response after ASCT(14). 
The main messages
ASCT is the best option for patients with chemosensitive 
relapse DLBCL, is associated with a significant survival benefit 
and is recommended as part of salvage therapy for these patients.
The age higher than 60 years is not an absolute 
contraindication for ASCT. But, ASCT outcomes as well as 
transplant-related mortality, relapse and survival in older adults 
are not as good as in younger patients.
ASCT using peripheral blood is not associated with 
survival benefit or improved tumor control in comparison to 
bone marrow. However, ASCT using peripheral blood is safer 
and easier to use with faster engraftment and lower rate of death 
due to infection, hence peripheral blood is the standard for 
autologous stem cell source. 
There is not sufficient evidence to recommend maintenance 
with rituximab outside a clinical trial after ASCT. 
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